<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>High Prevalence Antigens | Blood Bank</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="High-prevalence antigens, sometimes called “public” antigens, are red cell markers found on the vast majority of the population, often exceeding 99% frequency. While their presence is the norm,...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="High Prevalence Antigens | Blood Bank">
<meta property="og:type" content="book">
<meta property="og:description" content="High-prevalence antigens, sometimes called “public” antigens, are red cell markers found on the vast majority of the population, often exceeding 99% frequency. While their presence is the norm,...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="High Prevalence Antigens | Blood Bank">
<meta name="twitter:description" content="High-prevalence antigens, sometimes called “public” antigens, are red cell markers found on the vast majority of the population, often exceeding 99% frequency. While their presence is the norm,...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><link rel="icon" type="image/png" href="imgs/favicon.png">
<meta name="google-adsense-account" content="ca-pub-1344282930858290">
<script async src="https://www.googletagmanager.com/gtag/js?id=G-JERRQQFPF4"></script><script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-JERRQQFPF4');
    </script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
<link rel="stylesheet" href="toc.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Blood Bank</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li><a class="" href="content-areas.html">Content Areas</a></li>
<li><a class="" href="author.html">Author</a></li>
<li><a class="" href="ascp-boc.html">ASCP BOC</a></li>
<li><a class="" href="reading-list.html">Reading List</a></li>
<li class="book-part">Blood Products</li>
<li><a class="" href="donors.html">Donors</a></li>
<li><a class="" href="qualification.html">Qualification</a></li>
<li><a class="" href="processing.html">Processing</a></li>
<li><a class="" href="adverse-reactions-1.html">Adverse Reactions</a></li>
<li><a class="" href="special-donations-1.html">Special Donations</a></li>
<li><a class="" href="processing-1.html">Processing</a></li>
<li><a class="" href="fda-aabb-requirements.html">FDA, AABB Requirements</a></li>
<li><a class="" href="testing.html">Testing</a></li>
<li><a class="" href="labeling.html">Labeling</a></li>
<li><a class="" href="storage.html">Storage</a></li>
<li><a class="" href="anticoagulantsadditives.html">Anticoagulants/Additives</a></li>
<li><a class="" href="temperature-requirements.html">Temperature Requirements</a></li>
<li><a class="" href="transportation.html">Transportation</a></li>
<li><a class="" href="stored-products.html">Stored Products</a></li>
<li><a class="" href="expiration.html">Expiration</a></li>
<li><a class="" href="blood-components.html">Blood Components</a></li>
<li><a class="" href="red-blood-cells.html">Red Blood Cells</a></li>
<li><a class="" href="cryoprecipitated-ahf.html">Cryoprecipitated AHF</a></li>
<li><a class="" href="platelets.html">Platelets</a></li>
<li><a class="" href="plasma.html">Plasma</a></li>
<li><a class="" href="granulocytes.html">Granulocytes</a></li>
<li><a class="" href="wbc-reduced-components.html">WBC-Reduced Components</a></li>
<li><a class="" href="frozendeglycerolized-rbcs.html">Frozen/Deglycerolized RBCs</a></li>
<li><a class="" href="apheresis-products.html">Apheresis Products</a></li>
<li><a class="" href="fractionation-products.html">Fractionation Products</a></li>
<li><a class="" href="whole-blood.html">Whole Blood</a></li>
<li><a class="" href="washed-rbcs.html">Washed RBCs</a></li>
<li><a class="" href="rejuvenated-rbcs.html">Rejuvenated RBCs</a></li>
<li><a class="" href="irradiated-components.html">Irradiated Components</a></li>
<li><a class="" href="hematopoietic-progenitors.html">Hematopoietic Progenitors</a></li>
<li><a class="" href="blood-component-qc.html">Blood Component QC</a></li>
<li class="book-part">Blood Group Systems</li>
<li><a class="" href="genetics.html">Genetics</a></li>
<li><a class="" href="basic.html">Basic</a></li>
<li><a class="" href="molecular.html">Molecular</a></li>
<li><a class="" href="blood-group-inheritance.html">Blood Group Inheritance</a></li>
<li><a class="" href="biochemistryantigens.html">Biochemistry/Antigens</a></li>
<li><a class="" href="abo.html">ABO</a></li>
<li><a class="" href="lewis.html">Lewis</a></li>
<li><a class="" href="rh.html">Rh</a></li>
<li><a class="" href="mns.html">MNS</a></li>
<li><a class="" href="p1pkglobosidep.html">P1PK/Globoside(P)</a></li>
<li><a class="" href="ii.html">Ii</a></li>
<li><a class="" href="kell.html">Kell</a></li>
<li><a class="" href="kidd.html">Kidd</a></li>
<li><a class="" href="duffy.html">Duffy</a></li>
<li><a class="" href="lutheran.html">Lutheran</a></li>
<li><a class="" href="other-blood-groups.html">Other Blood Groups</a></li>
<li><a class="active" href="high-prevalence-antigens.html">High Prevalence Antigens</a></li>
<li><a class="" href="low-prevalence-antigens.html">Low Prevalence Antigens</a></li>
<li><a class="" href="hla.html">HLA</a></li>
<li><a class="" href="platelet-specific.html">Platelet-Specific</a></li>
<li><a class="" href="granulocyte-specific.html">Granulocyte-Specific</a></li>
<li><a class="" href="role-of-blood-groups-in-transfusion.html">Role of Blood Groups in Transfusion</a></li>
<li><a class="" href="immunogenicity.html">Immunogenicity</a></li>
<li><a class="" href="antigen-prevalence.html">Antigen Prevalence</a></li>
<li class="book-part">Immunology &amp; Physiology</li>
<li><a class="" href="immunology.html">Immunology</a></li>
<li><a class="" href="immune-response.html">Immune response</a></li>
<li><a class="" href="primary-secondary.html">Primary &amp; Secondary</a></li>
<li><a class="" href="b-t-cells-macrophages.html">B &amp; T cells, Macrophages</a></li>
<li><a class="" href="genetics-1.html">Genetics</a></li>
<li><a class="" href="immunoglobulins.html">Immunoglobulins</a></li>
<li><a class="" href="classes-subclasses.html">Classes &amp; Subclasses</a></li>
<li><a class="" href="structure.html">Structure</a></li>
<li><a class="" href="properties.html">Properties</a></li>
<li><a class="" href="ag-ab-interactions.html">Ag-Ab Interactions</a></li>
<li><a class="" href="principles.html">Principles</a></li>
<li><a class="" href="testing-1.html">Testing</a></li>
<li><a class="" href="complement.html">Complement</a></li>
<li><a class="" href="pathway-mechanisms.html">Pathway Mechanisms</a></li>
<li><a class="" href="biologic-properties.html">Biologic Properties</a></li>
<li><a class="" href="physiology-pathophysiology.html">Physiology &amp; Pathophysiology</a></li>
<li><a class="" href="blood-physiology.html">Blood Physiology</a></li>
<li><a class="" href="circulation-volume.html">Circulation &amp; Volume</a></li>
<li><a class="" href="composition-function.html">Composition &amp; Function</a></li>
<li><a class="" href="cell-survival.html">Cell Survival</a></li>
<li><a class="" href="cell-metabolism.html">Cell Metabolism</a></li>
<li><a class="" href="hemostasis-coagulation.html">Hemostasis &amp; Coagulation</a></li>
<li><a class="" href="factors-disorders.html">Factors &amp; Disorders</a></li>
<li><a class="" href="plt-functions-disorders.html">PLT Functions &amp; Disorders</a></li>
<li><a class="" href="hdfn.html">HDFN</a></li>
<li><a class="" href="pathophysiology.html">Pathophysiology</a></li>
<li><a class="" href="detection.html">Detection</a></li>
<li><a class="" href="treatment.html">Treatment</a></li>
<li><a class="" href="prevention.html">Prevention</a></li>
<li><a class="" href="cytopenias-1.html">Cytopenias</a></li>
<li><a class="" href="anemia.html">Anemia</a></li>
<li><a class="" href="thrombocytopenia.html">Thrombocytopenia</a></li>
<li><a class="" href="neutropenia.html">Neutropenia</a></li>
<li><a class="" href="transplantation-1.html">Transplantation</a></li>
<li><a class="" href="solid-organ.html">Solid Organ</a></li>
<li><a class="" href="hpc.html">HPC</a></li>
<li class="book-part">Serology &amp; Molecular</li>
<li><a class="" href="routine-tests.html">Routine Tests</a></li>
<li><a class="" href="blood-grouping.html">Blood Grouping</a></li>
<li><a class="" href="compatibility.html">Compatibility</a></li>
<li><a class="" href="antibody-detection.html">Antibody Detection</a></li>
<li><a class="" href="crossmatch.html">Crossmatch</a></li>
<li><a class="" href="ab-id-significance.html">Ab ID &amp; Significance</a></li>
<li><a class="" href="dat.html">DAT</a></li>
<li><a class="" href="reagents.html">Reagents</a></li>
<li><a class="" href="antiglobulin-sera.html">Antiglobulin Sera</a></li>
<li><a class="" href="blood-grouping-sera.html">Blood Grouping Sera</a></li>
<li><a class="" href="reagent-rbcs.html">Reagent RBCs</a></li>
<li><a class="" href="special-tests-reagents.html">Special Tests &amp; Reagents</a></li>
<li><a class="" href="enzymes.html">Enzymes</a></li>
<li><a class="" href="enhancement-media.html">Enhancement Media</a></li>
<li><a class="" href="lectins.html">Lectins</a></li>
<li><a class="" href="adsorptions.html">Adsorptions</a></li>
<li><a class="" href="elutions.html">Elutions</a></li>
<li><a class="" href="titrations-1.html">Titrations</a></li>
<li><a class="" href="cell-separations.html">Cell Separations</a></li>
<li><a class="" href="elisa.html">ELISA</a></li>
<li><a class="" href="molecular-techniques.html">Molecular Techniques</a></li>
<li><a class="" href="neutralization.html">Neutralization</a></li>
<li><a class="" href="thiol-reagents.html">Thiol Reagents</a></li>
<li><a class="" href="immunofluorescence.html">Immunofluorescence</a></li>
<li><a class="" href="solid-phase.html">Solid Phase</a></li>
<li><a class="" href="column-agglutination.html">Column Agglutination</a></li>
<li><a class="" href="chloroquine-diphosphate.html">Chloroquine Diphosphate</a></li>
<li><a class="" href="edta-glycine-acid.html">EDTA-Glycine Acid</a></li>
<li><a class="" href="quality-assurance.html">Quality Assurance</a></li>
<li><a class="" href="blood-samples.html">Blood Samples</a></li>
<li><a class="" href="reagents-1.html">Reagents</a></li>
<li><a class="" href="test-procedures.html">Test Procedures</a></li>
<li class="book-part">Transfusion Practice</li>
<li><a class="" href="indications.html">Indications</a></li>
<li><a class="" href="component-therapy.html">Component Therapy</a></li>
<li><a class="" href="adverse-effects.html">Adverse Effects</a></li>
<li><a class="" href="immunologic.html">Immunologic</a></li>
<li><a class="" href="nonimmunologic.html">Nonimmunologic</a></li>
<li><a class="" href="ttds.html">TTDs</a></li>
<li><a class="" href="apheresis-extracorporeal-circulation.html">Apheresis &amp; Extracorporeal Circulation</a></li>
<li><a class="" href="blood-administration-patient-blood-management.html">Blood Administration &amp; Patient Blood Management</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Blood-Bank/blob">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="high-prevalence-antigens" class="section level1 unnumbered">
<h1>High Prevalence Antigens<a class="anchor" aria-label="anchor" href="#high-prevalence-antigens"><i class="fas fa-link"></i></a>
</h1>
<p>High-prevalence antigens, sometimes called “public” antigens, are red cell markers found on the vast majority of the population, often exceeding 99% frequency. While their presence is the norm, their significance in transfusion medicine arises dramatically when a rare individual <em>lacks</em> one of these common antigens and develops a corresponding antibody. This scenario poses a critical challenge: finding compatible (antigen-negative) blood becomes exceptionally difficult, often requiring extensive screening and coordination through rare donor networks</p>
<div id="antigens-of-high-prevalence-the-common-denominators" class="section level2 unnumbered">
<h2>
<strong>Antigens of High Prevalence: The Common Denominators</strong><a class="anchor" aria-label="anchor" href="#antigens-of-high-prevalence-the-common-denominators"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A high-prevalence antigen (sometimes called a public antigen) is a red blood cell surface antigen expressed by almost everyone in a given population (or across multiple populations)</li>
</ul>
</div>
<div id="why-are-they-important-in-blood-bank" class="section level2 unnumbered">
<h2>
<strong>Why are they important in Blood Bank?</strong><a class="anchor" aria-label="anchor" href="#why-are-they-important-in-blood-bank"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Antibodies are Rare:</strong> Because most people <em>have</em> the antigen, they usually won’t make an antibody against it (due to self-tolerance). Therefore, antibodies to high-prevalence antigens are infrequently encountered</li>
<li>
<strong>The Compatibility Crisis:</strong> <em>When</em> someone <em>does</em> form an antibody to a high-prevalence antigen (because they are one of the rare individuals lacking it), finding compatible (antigen-negative) blood becomes extremely difficult. Imagine needing blood negative for an antigen that 99.9% of donors have!</li>
<li>
<strong>Clinical Significance:</strong> Many antibodies against high-prevalence antigens are <strong>clinically significant</strong>, capable of causing Hemolytic Transfusion Reactions (HTR) and/or Hemolytic Disease of the Fetus and Newborn (HDFN)</li>
<li>
<strong>Key Biochemical Carriers:</strong> These antigens can reside on various structures: glycoproteins (like Kell, Lutheran, Gerbich), proteins (like Band 3/Diego, Aquaporin-1/Colton), or even carbohydrate structures (like I, P)</li>
</ul>
</div>
<div id="examples-of-important-high-prevalence-antigens" class="section level2 unnumbered">
<h2>
<strong>Examples of Important High-Prevalence Antigens</strong><a class="anchor" aria-label="anchor" href="#examples-of-important-high-prevalence-antigens"><i class="fas fa-link"></i></a>
</h2>
<p>Note: This isn’t exhaustive, but covers many clinically relevant examples</p>
<div id="k-cellano---kell-system-kel-isbt-006" class="section level3 unnumbered">
<h3>
<strong>k (Cellano) - Kell System (KEL, ISBT 006)</strong><a class="anchor" aria-label="anchor" href="#k-cellano---kell-system-kel-isbt-006"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Kell glycoprotein</li>
<li>
<strong>Prevalence:</strong> &gt;99% in Caucasians, &gt;99.9% in Black populations. Antithetical to K (Kpa)</li>
<li>
<strong>Antibody (Anti-k):</strong> IgG, clinically significant (HTR, HDFN). Finding k-negative (K+k-) blood is difficult</li>
<li>
<strong>Antigen-Negative:</strong> K+k- individuals. Extremely rare K<sub>0</sub> (Kell null) individuals lack all Kell antigens</li>
</ul>
</div>
<div id="kpb---kell-system-kel-isbt-006" class="section level3 unnumbered">
<h3>
<strong>Kp<sup>b</sup> - Kell System (KEL, ISBT 006)</strong><a class="anchor" aria-label="anchor" href="#kpb---kell-system-kel-isbt-006"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Kell glycoprotein</li>
<li>
<strong>Prevalence:</strong> &gt;99.9% in most populations. Antithetical to Kp<sup>a</sup>
</li>
<li>
<strong>Antibody (Anti-Kp<sup>b</sup>):</strong> IgG, clinically significant (HTR, HDFN). Finding Kp(b-) blood is very difficult</li>
<li>
<strong>Antigen-Negative:</strong> Kp(a+b-) or Kp(a-b-) (K<sub>0</sub>)</li>
</ul>
</div>
<div id="jsb---kell-system-kel-isbt-006" class="section level3 unnumbered">
<h3>
<strong>Js<sup>b</sup> - Kell System (KEL, ISBT 006)</strong><a class="anchor" aria-label="anchor" href="#jsb---kell-system-kel-isbt-006"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Kell glycoprotein</li>
<li>
<strong>Prevalence:</strong> &gt;99.9% in Caucasians, ~80% in Black populations (Js<sup>a</sup> is more common in Black populations). Antithetical to Js<sup>a</sup>
</li>
<li>
<strong>Antibody (Anti-Js<sup>b</sup>):</strong> IgG, clinically significant (HTR, HDFN). Finding Js(b-) blood is difficult, especially for non-Black patients</li>
<li>
<strong>Antigen-Negative:</strong> Js(a+b-)</li>
</ul>
</div>
<div id="lub---lutheran-system-lu-isbt-005" class="section level3 unnumbered">
<h3>
<strong>Lu<sup>b</sup> - Lutheran System (LU, ISBT 005)</strong><a class="anchor" aria-label="anchor" href="#lub---lutheran-system-lu-isbt-005"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Lutheran glycoprotein (BCAM)</li>
<li>
<strong>Prevalence:</strong> &gt;99% in most populations. Antithetical to Lu<sup>a</sup>
</li>
<li>
<strong>Antibody (Anti-Lu<sup>b</sup>):</strong> Usually IgG, sometimes IgM/mixed. Can cause mild-moderate HTR (often delayed) and mild HDFN</li>
<li>
<strong>Antigen-Negative:</strong> Lu(a+b-) or rare Lu(a-b-) null phenotypes. Finding Lu(b-) blood is difficult</li>
</ul>
</div>
<div id="u---mns-system-mns-isbt-002" class="section level3 unnumbered">
<h3>
<strong>U - MNS System (MNS, ISBT 002)</strong><a class="anchor" aria-label="anchor" href="#u---mns-system-mns-isbt-002"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Associated with Glycophorin B (GPB). Present when either S or s antigen is expressed normally</li>
<li>
<strong>Prevalence:</strong> &gt;99.9% in Caucasians, slightly lower but still very high in Black populations (~99%)</li>
<li>
<strong>Antibody (Anti-U):</strong> IgG, <strong>highly clinically significant</strong> (severe HTR, severe HDFN)</li>
<li>
<strong>Antigen-Negative:</strong> U-negative individuals are almost exclusively of African descent and lack GPB (usually S-s- phenotype). Finding U-negative blood is extremely challenging and requires screening donors of African ancestry</li>
</ul>
</div>
<div id="i---i-system-i-isbt-027" class="section level3 unnumbered">
<h3>
<strong>I - I System (I, ISBT 027)</strong><a class="anchor" aria-label="anchor" href="#i---i-system-i-isbt-027"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Branched carbohydrate structure on precursor chains (related to ABO). ‘I’ develops from fetal ‘i’ antigen during the first ~18 months of life</li>
<li>
<strong>Prevalence:</strong> Virtually 100% in adults. (Fetal/newborn cells are rich in i, poor in I)</li>
<li>
<strong>Antibody (Anti-I):</strong> Usually a benign, <strong>cold-reacting IgM autoantibody</strong>. Can cause issues in cold temperatures (Cold Agglutinin Disease) or interfere with room temperature/immediate spin testing. Pathologic anti-I can be potent IgM hemolysins. Alloanti-I is extremely rare (seen in adult i phenotype individuals)</li>
<li>
<strong>Antigen-Negative:</strong> Rare adult i phenotype individuals</li>
</ul>
</div>
<div id="vel---vel-system-vel-isbt-035" class="section level3 unnumbered">
<h3>
<strong>Vel - Vel System (VEL, ISBT 035)</strong><a class="anchor" aria-label="anchor" href="#vel---vel-system-vel-isbt-035"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Carried on protein SMIM1</li>
<li>
<strong>Prevalence:</strong> &gt;99.9% in most populations</li>
<li>
<strong>Antibody (Anti-Vel):</strong> Often mixed IgG/IgM, potent complement activator. <strong>Highly clinically significant</strong> (severe immediate HTR). Known for being difficult to identify serologically (weak/variable reactions)</li>
<li>
<strong>Antigen-Negative:</strong> Vel-negative phenotype is very rare (&lt;0.01%). Finding Vel-negative blood is exceptionally difficult, relying heavily on rare donor registries</li>
</ul>
</div>
<div id="j-mh-john-milton-hagen---j-mh-system-j-mh-isbt-026" class="section level3 unnumbered">
<h3>
<strong>J MH (John Milton Hagen) - J MH System (J MH, ISBT 026)</strong><a class="anchor" aria-label="anchor" href="#j-mh-john-milton-hagen---j-mh-system-j-mh-isbt-026"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Located on Semaphorin 7A (CD108), a GPI-linked protein</li>
<li>
<strong>Prevalence:</strong> &gt;99.9% in most populations</li>
<li>
<strong>Antibody (Anti-J MH):</strong> Usually IgG, often weak, refractile, and difficult to work with (“nebulous”). Generally considered <strong>clinically insignificant</strong> or only causing mild RBC destruction. Can mask other significant antibodies. Antigen expression can be weak or variable</li>
<li>
<strong>Antigen-Negative:</strong> J MH-negative is extremely rare</li>
</ul>
</div>
<div id="dib---diego-system-di-isbt-010" class="section level3 unnumbered">
<h3>
<strong>Di<sup>b</sup> - Diego System (DI, ISBT 010)</strong><a class="anchor" aria-label="anchor" href="#dib---diego-system-di-isbt-010"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Located on Band 3 protein (Anion Exchanger 1)</li>
<li>
<strong>Prevalence:</strong> &gt;99.9% in most non-Asian/Native American populations. Antithetical to Di<sup>a</sup>
</li>
<li>
<strong>Antibody (Anti-Di<sup>b</sup>):</strong> IgG, clinically significant (HTR, HDFN)</li>
<li>
<strong>Antigen-Negative:</strong> Di(a+b-) individuals (more common in East Asian/Native American populations)</li>
</ul>
</div>
<div id="wrb---diego-system-di-isbt-010" class="section level3 unnumbered">
<h3>
<strong>Wr<sup>b</sup> - Diego System (DI, ISBT 010)</strong><a class="anchor" aria-label="anchor" href="#wrb---diego-system-di-isbt-010"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Requires interaction between Band 3 and Glycophorin A</li>
<li>
<strong>Prevalence:</strong> &gt;99.9% in most populations. Antithetical to Wr<sup>a</sup>
</li>
<li>
<strong>Antibody (Anti-Wr<sup>b</sup>):</strong> Extremely rare (as antigen is high prevalence). Can be IgG, potentially significant. More common is autoanti-Wr<sup>b</sup> in Warm Autoimmune Hemolytic Anemia (WAIHA)</li>
<li>
<strong>Antigen-Negative:</strong> Wr(a+b-) individuals</li>
</ul>
</div>
<div id="coa---colton-system-co-isbt-015" class="section level3 unnumbered">
<h3>
<strong>Co<sup>a</sup> - Colton System (CO, ISBT 015)</strong><a class="anchor" aria-label="anchor" href="#coa---colton-system-co-isbt-015"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Located on Aquaporin-1 (water channel)</li>
<li>
<strong>Prevalence:</strong> &gt;99.7% in most populations. Antithetical to Co<sup>b</sup>
</li>
<li>
<strong>Antibody (Anti-Co<sup>a</sup>):</strong> IgG, clinically significant (HTR, HDFN)</li>
<li>
<strong>Antigen-Negative:</strong> Co(a-b+) or rare Co(a-b-) null phenotype</li>
</ul>
</div>
<div id="ge3---gerbich-system-ge-isbt-020" class="section level3 unnumbered">
<h3>
<strong>Ge3 - Gerbich System (GE, ISBT 020)</strong><a class="anchor" aria-label="anchor" href="#ge3---gerbich-system-ge-isbt-020"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Located on Glycophorin C (GPC) and Glycophorin D (GPD)</li>
<li>
<strong>Prevalence:</strong> &gt;99% in most populations</li>
<li>
<strong>Antibody (Anti-Ge3):</strong> IgG, clinically significant (HTR, HDFN)</li>
<li>
<strong>Antigen-Negative:</strong> Individuals with Gerbich null phenotypes (e.g., Ge:-2,-3,-4 or Leach phenotype). Finding Ge3-negative blood is difficult</li>
</ul>
</div>
<div id="emm---emm-system-emm-isbt-044" class="section level3 unnumbered">
<h3>
<strong>Emm - EMM System (EMM, ISBT 044)</strong><a class="anchor" aria-label="anchor" href="#emm---emm-system-emm-isbt-044"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Biochemistry:</strong> Unknown protein carrier (as of recent knowledge, may be updated)</li>
<li>
<strong>Prevalence:</strong> &gt;99.99% (extremely high)</li>
<li>
<strong>Antibody (Anti-Emm):</strong> IgG, potent complement activator. <strong>Highly clinically significant</strong> (severe HTR, HDFN)</li>
<li>
<strong>Antigen-Negative:</strong> Emm-negative phenotype is exceedingly rare. Finding compatible blood requires extensive international collaboration</li>
</ul>
</div>
</div>
<div id="challenges-and-management" class="section level2 unnumbered">
<h2>
<strong>Challenges and Management</strong><a class="anchor" aria-label="anchor" href="#challenges-and-management"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Identification:</strong> Confirming the antibody specificity often requires testing against a panel of rare antigen-negative cells, typically done in an Immunohematology Reference Laboratory (IRL)</li>
<li>
<strong>Finding Compatible Blood:</strong> This is the major hurdle. Strategies include:
<ul>
<li>Screening large numbers of donors (thousands)</li>
<li>Utilizing national and international <strong>Rare Donor Programs</strong>
</li>
<li>Testing family members (siblings have a 1 in 4 chance of having the same rare phenotype)</li>
<li>
<strong>Autologous donation:</strong> (patient donating for themselves) if the need is anticipated and the patient is eligible</li>
<li>Molecular genotyping of donors can sometimes help identify rare antigen-negative units more efficiently</li>
</ul>
</li>
<li>
<strong>Clinical Decisions:</strong> Balancing the risk of transfusion reaction vs. the risk of delaying transfusion. Sometimes, the “least incompatible” blood might be considered in emergencies if truly antigen-negative blood is unavailable, but this carries significant risk</li>
</ul>
</div>
<div id="key-terms-41" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-41"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>High-Prevalence Antigen:</strong> An antigen found on the red blood cells of a very large percentage (typically &gt;99%) of a given population</li>
<li>
<strong>Null Phenotype:</strong> A rare phenotype where an individual lacks all antigens within a specific blood group system (e.g., K<sub>0</sub>, Rh<sub>null</sub>, Lu(a-b-)). These individuals may produce complex antibodies reacting with all cells except those of the same null type</li>
<li>
<strong>Rare Donor Program:</strong> A system or registry (often national or international) that catalogs donors known to have rare blood types (lacking high-prevalence antigens or possessing combinations of uncommon antigens) to facilitate finding compatible blood for patients with rare antibodies</li>
<li>
<strong>Reference Laboratory (Immunohematology Reference Laboratory - IRL):</strong> A specialized laboratory equipped with the reagents (including rare antisera and antigen-typed cells), techniques, and expertise to investigate and resolve complex immunohematology problems, including identifying antibodies to high- and low-prevalence antigens</li>
<li>
<strong>Clinically Significant (Antibody):</strong> An antibody capable of causing adverse reactions to transfusion (Hemolytic Transfusion Reactions - HTR) or causing Hemolytic Disease of the Fetus and Newborn (HDFN). Many antibodies to high-prevalence antigens fall into this category</li>
<li>
<strong>Antithetical Antigen:</strong> One of a pair of antigens encoded by alleles at the same gene locus (e.g., K and k, Fy<sup>a</sup> and Fy<sup>b</sup>). If an antigen is high prevalence (like k), its antithetical partner (K) is often low prevalence</li>
</ul>
</div>
</div>
<!-- Scoll to TOC element -->
<script defer>
  // adjust TOC scroll to selected element/topic
  function scroll_to_element() {
    header_height = document.getElementsByTagName('header')[0].offsetHeight/2;
    toc_element_position = document.querySelector('.book-toc > li > a.active').offsetTop;
    if(document.querySelector('.book-toc > li > a.active').offsetLeft == 0) {
      toc_element_position1 = document.querySelector('.book-toc > li > a.active').offsetParent.offsetTop;
      toc_element_position2 = document.querySelector('.book-toc > li > a.active').offsetParent.offsetHeight;
      toc_element_position = toc_element_position1 + toc_element_position2;
    }
    document.getElementsByTagName('header')[0].scrollTo(0, toc_element_position - header_height, 'smooth');
  }
  window.onload = scroll_to_element();

  // hide those labes that take up multiple lines
  sections = [];
  topics = [];
  function hide_label() {
    // sections
    document
      .querySelectorAll('.book-toc > li')
      .forEach(elem => {
        window
          .getComputedStyle(elem)
          .textTransform === "uppercase"
          &&
          elem.classList
          .contains('book-part')
          ? sections.push(elem)
          : '';
      });

    // topics
    document
      .querySelectorAll('.book-toc > li')
      .forEach(elem => {
        window
          .getComputedStyle(elem)
          .textTransform === "uppercase"
          &&
          !elem.classList
          .contains('book-part')
          ? topics.push(elem)
          : '';
      });
  }
  hide_label();
  head = document.getElementsByTagName('header')[0];
  head.addEventListener('scroll', () => {
    // sections
    count_sections = 0;
    prev_sections_elem = '';
    sections
      .forEach((elem) => {
      if(count_sections === 0) {
        initial_y = elem.getBoundingClientRect().y + 20;
        count_sections = 1;
      } else {
        if(elem.getBoundingClientRect().y < initial_y) {
          prev_sections_elem.classList.add('hide_label');
        } else {
          prev_sections_elem.classList.remove('hide_label');
        }
      }
      prev_sections_elem = elem;
    });
    // topics
    count_topics = 0;
    prev_topic_elem = '';
    topics
      .forEach((elem) => {
      if(count_topics === 0) {
        initial_y = elem.getBoundingClientRect().y + 20;
        count_topics = 1;
      } else {
        if(elem.getBoundingClientRect().y < initial_y) {
          prev_topic_elem.classList.add('hide_label');
        } else {
          prev_topic_elem.classList.remove('hide_label');
        }
      }
      prev_topic_elem = elem;
    });
  });
</script><div class="chapter-nav">
<div class="prev"><a href="other-blood-groups.html">Other Blood Groups</a></div>
<div class="next"><a href="low-prevalence-antigens.html">Low Prevalence Antigens</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#high-prevalence-antigens">High Prevalence Antigens</a></li>
<li><a class="nav-link" href="#antigens-of-high-prevalence-the-common-denominators">Antigens of High Prevalence: The Common Denominators</a></li>
<li><a class="nav-link" href="#why-are-they-important-in-blood-bank">Why are they important in Blood Bank?</a></li>
<li>
<a class="nav-link" href="#examples-of-important-high-prevalence-antigens">Examples of Important High-Prevalence Antigens</a><ul class="nav navbar-nav">
<li><a class="nav-link" href="#k-cellano---kell-system-kel-isbt-006">k (Cellano) - Kell System (KEL, ISBT 006)</a></li>
<li><a class="nav-link" href="#kpb---kell-system-kel-isbt-006">Kpb - Kell System (KEL, ISBT 006)</a></li>
<li><a class="nav-link" href="#jsb---kell-system-kel-isbt-006">Jsb - Kell System (KEL, ISBT 006)</a></li>
<li><a class="nav-link" href="#lub---lutheran-system-lu-isbt-005">Lub - Lutheran System (LU, ISBT 005)</a></li>
<li><a class="nav-link" href="#u---mns-system-mns-isbt-002">U - MNS System (MNS, ISBT 002)</a></li>
<li><a class="nav-link" href="#i---i-system-i-isbt-027">I - I System (I, ISBT 027)</a></li>
<li><a class="nav-link" href="#vel---vel-system-vel-isbt-035">Vel - Vel System (VEL, ISBT 035)</a></li>
<li><a class="nav-link" href="#j-mh-john-milton-hagen---j-mh-system-j-mh-isbt-026">J MH (John Milton Hagen) - J MH System (J MH, ISBT 026)</a></li>
<li><a class="nav-link" href="#dib---diego-system-di-isbt-010">Dib - Diego System (DI, ISBT 010)</a></li>
<li><a class="nav-link" href="#wrb---diego-system-di-isbt-010">Wrb - Diego System (DI, ISBT 010)</a></li>
<li><a class="nav-link" href="#coa---colton-system-co-isbt-015">Coa - Colton System (CO, ISBT 015)</a></li>
<li><a class="nav-link" href="#ge3---gerbich-system-ge-isbt-020">Ge3 - Gerbich System (GE, ISBT 020)</a></li>
<li><a class="nav-link" href="#emm---emm-system-emm-isbt-044">Emm - EMM System (EMM, ISBT 044)</a></li>
</ul>
</li>
<li><a class="nav-link" href="#challenges-and-management">Challenges and Management</a></li>
<li><a class="nav-link" href="#key-terms-41">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Blood-Bank/blob/blob/main/Rmd/02-B-12.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Blood-Bank/blob/edit/main/Rmd/02-B-12.Rmd" target="_blank">Edit this page <i class="fab fa-github"></i></a></li>
          <li><a id="buymeacoffee" href="https://buymeacoffee.com/bloodcellid" target="_blank">NEED Caffeine</a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-04-08 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
